X0202 SCHEDULE 13G/A 0001140361-25-042006 0002095697 XXXXXXXX LIVE 1 Common Stock, par value $0.0001 05/18/2026 0001806952 Lyell Immunopharma, Inc. 55083R203 201 Haskins Way South San Francisco CA 94080 Rule 13d-1(c) Innovative Cellular Therapeutics Holdings Limited b E9 3000000 0 3000000 0 3000000 12.3 OO (1) This percentage is calculated based upon 24,434,087 shares of Common Stock outstanding, representing the 23,334,087 shares reported outstanding as of May 1, 2026 on the cover of the Issuer's most recent Quarterly Report on Form 10-Q (for the quarter ended March 31, 2026), plus the 1,100,000 shares of Common Stock that the Reporting Person became entitled to receive as described herein (which shares are deemed outstanding for purposes of calculating the Reporting Person's beneficial ownership percentage). Lyell Immunopharma, Inc. 201 Haskins Way, South San Francisco, California 94080 This Schedule is filed by Innovative Cellular Therapeutics Holdings Limited, a Cayman Islands exempted company incorporated with limited liability (the "Reporting Person"). 190 Elgin Avenue, George Town, Grand Cayman KY1-9008 Cayman Islands. See Row 4 of the cover page. Y 3,000,000 shares of Common Stock. See Row 9 of the cover page. approximately 12.3%. See Row 11 of the cover page. 3,000,000. See Row 5. 0. See Row 6. 3,000,000. See Row 7. 0. See Row 8. Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. Innovative Cellular Therapeutics Holdings Limited /s/ Lei Xiao 06/18/2026 This Amendment No. 1 to Schedule 13G (this "Amendment") amends and supplements the Schedule 13G originally filed with the Securities and Exchange Commission on November 13, 2025 (the "Original Schedule 13G"), by Innovative Cellular Therapeutics Holdings Limited (the "Reporting Person") with respect to the common stock, par value $0.0001 per share (the "Common Stock"), of Lyell Immunopharma, Inc. (the "Issuer"). This Amendment is being filed to report that, on May 18, 2026, upon the achievement of a development milestone under the License Agreement, dated November 6, 2025, between the Issuer and the Reporting Person, the Reporting Person became entitled to receive, and acquired the right to acquire, an additional 1,100,000 shares of Common Stock. The Reporting Person is deemed to have acquired beneficial ownership of such shares on the date its right to receive them became fixed, thereby increasing the Reporting Person's aggregate beneficial ownership to 3,000,000 shares of Common Stock (approximately 12.3% of the class) and causing the Reporting Person to beneficially own more than 10% of the outstanding Common Stock. Except as expressly amended and supplemented by this Amendment, the Original Schedule 13G remains in full force and effect. Capitalized terms used but not defined herein have the meanings ascribed to them in the Original Schedule 13G.